233 related articles for article (PubMed ID: 29872267)
21. A Phase I/II Study of Biweekly Carboplatin and Nab-paclitaxel With Concurrent Radiotherapy for Patients With Locally Advanced Unresectable Stage III Non-small-cell Lung Cancer.
Tanaka H; Hasegawa Y; Makiguchi T; Okumura F; Tabe C; Shiratori T; Ishioka Y; Itoga M; Taima K; Yokouchi J; Hatayama Y; Aoki M; Tasaka S
Clin Lung Cancer; 2021 Jan; 22(1):42-48. PubMed ID: 33158764
[TBL] [Abstract][Full Text] [Related]
22. A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer.
Villaruz LC; Cobo M; Syrigos K; Mavroudis D; Zhang W; Kim JS; Socinski MA
Lung Cancer; 2019 Oct; 136():52-56. PubMed ID: 31445354
[TBL] [Abstract][Full Text] [Related]
23. The Safety and Efficacy of Treatment with Nab-paclitaxel and Carboplatin for Patients with Advanced Squamous Non-small Cell Lung Cancer Concurrent with Idiopathic Interstitial Pneumonias.
Fujita T; Hiroishi T; Shikano K; Yanagisawa A; Hayama N; Amano H; Nakamura M; Hirano S; Tabeta H; Nakamura S
Intern Med; 2018 Jul; 57(13):1827-1832. PubMed ID: 29434143
[TBL] [Abstract][Full Text] [Related]
24. A phase II study of nab-paclitaxel plus carboplatin in combination with thoracic radiation in patients with locally advanced non-small-cell lung cancer.
Hasegawa T; Futamura Y; Horiba A; Yoshida T; Suzuki T; Kato T; Kaito D; Ohno Y; Iida T; Hayashi S; Sawa T
J Radiat Res; 2016 Jan; 57(1):50-4. PubMed ID: 26442970
[TBL] [Abstract][Full Text] [Related]
25. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.
Herbst RS; Redman MW; Kim ES; Semrad TJ; Bazhenova L; Masters G; Oettel K; Guaglianone P; Reynolds C; Karnad A; Arnold SM; Varella-Garcia M; Moon J; Mack PC; Blanke CD; Hirsch FR; Kelly K; Gandara DR
Lancet Oncol; 2018 Jan; 19(1):101-114. PubMed ID: 29169877
[TBL] [Abstract][Full Text] [Related]
26. Retrospective analysis of the effectiveness and tolerability of nab-paclitaxel in Chinese elderly patients with advanced non-small-cell lung carcinoma.
Wang S; Liang Q; Chi Y; Zhuo M; An T; Duan J; Wang Z; Wang Y; Zhong J; Yang X; Chen H; Wang J; Zhao J
Thorac Cancer; 2020 May; 11(5):1149-1159. PubMed ID: 32162417
[TBL] [Abstract][Full Text] [Related]
27. Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non-small cell lung cancer.
Kawano Y; Sasaki T; Yamaguchi H; Hirano K; Horiike A; Satouchi M; Hosokawa S; Morinaga R; Komiya K; Inoue K; Fujita Y; Toyozawa R; Kimura T; Takahashi K; Nishikawa K; Kishimoto J; Nakanishi Y; Okamoto I
Lung Cancer; 2018 Nov; 125():136-141. PubMed ID: 30429011
[TBL] [Abstract][Full Text] [Related]
28. Atezolizumab plus carboplatin and nab-paclitaxel versus carboplatin and nab-paclitaxel as treatments for Chinese, treatment-naïve, stage IV, non-squamous, non-small-cell lung cancer patients: A retrospective analysis.
Chen Y; Kang S; Yan M
Pharmacol Res Perspect; 2022 Jun; 10(3):e00941. PubMed ID: 35568997
[TBL] [Abstract][Full Text] [Related]
29. Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab-Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer.
Tsuchiya-Kawano Y; Sasaki T; Yamaguchi H; Hirano K; Horiike A; Satouchi M; Hosokawa S; Morinaga R; Komiya K; Inoue K; Fujita Y; Toyozawa R; Kimura T; Takahashi K; Nishikawa K; Kishimoto J; Nakanishi Y; Okamoto I
Oncologist; 2020 Jun; 25(6):475-e891. PubMed ID: 31649134
[TBL] [Abstract][Full Text] [Related]
30. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L
J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
[TBL] [Abstract][Full Text] [Related]
31. Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab-paclitaxel for non-squamous non-small cell lung cancer with malignant pleural effusion.
Tamiya M; Tamiya A; Suzuki H; Taniguchi Y; Katayama K; Minomo S; Nakao K; Takeuchi N; Matsuda Y; Naito Y; Shiroyama T; Okamoto N; Okishio K; Kumagai T; Atagi S; Imamura F; Hirashima T
Invest New Drugs; 2021 Aug; 39(4):1106-1112. PubMed ID: 33544282
[TBL] [Abstract][Full Text] [Related]
32. Nanoparticle albumin-bound paclitaxel in elder patients with advanced squamous non-small-cell lung cancer: A retrospective study.
Liu Y; Dong Y; Zhu H; Jing W; Guo H; Yu J
Cancer Med; 2020 Feb; 9(4):1365-1373. PubMed ID: 31876976
[TBL] [Abstract][Full Text] [Related]
33. nab-paclitaxel for the management of patients with advanced non-small-cell lung cancer.
Hirsh V
Expert Rev Anticancer Ther; 2014 Feb; 14(2):129-41. PubMed ID: 24467217
[TBL] [Abstract][Full Text] [Related]
34. A multi-institutional randomized phase III study comparing weekly carboplatin plus nab-paclitaxel and daily low-dose carboplatin as regimens for concurrent chemoradiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer: Japan Clinical Oncology Group Study JCOG1914.
Shimoyama R; Omori S; Nomura S; Kenmotsu H; Takahashi T; Harada H; Ishikura S; Mizutani T; Ando M; Kataoka T; Fukuda H; Ohe Y;
Jpn J Clin Oncol; 2021 Apr; 51(5):836-841. PubMed ID: 33728436
[TBL] [Abstract][Full Text] [Related]
35. Treatment Rationale and Design for J-SONIC: A Randomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced Non-Small-cell Lung Cancer With Idiopathic Pulmonary Fibrosis.
Otsubo K; Kishimoto J; Kenmotsu H; Minegishi Y; Ichihara E; Shiraki A; Kato T; Atagi S; Horinouchi H; Ando M; Kondoh Y; Kusumoto M; Ichikado K; Yamamoto N; Nakanishi Y; Okamoto I
Clin Lung Cancer; 2018 Jan; 19(1):e5-e9. PubMed ID: 28687482
[TBL] [Abstract][Full Text] [Related]
36. A Randomized Phase III Study Comparing Carboplatin With Nab-Paclitaxel Versus Docetaxel for Elderly Patients With Squamous-Cell Lung Cancer: Study Protocol.
Kogure Y; Saka H; Takiguchi Y; Atagi S; Kurata T; Ebi N; Inoue A; Kubota K; Takenoyama M; Seto T; Kada A; Yamanaka T; Ando M; Yamamoto N; Gemma A; Ichinose Y
Clin Lung Cancer; 2018 Sep; 19(5):e711-e715. PubMed ID: 29861395
[TBL] [Abstract][Full Text] [Related]
37. Clinical investigation of efficacy of albumin bound paclitaxel plus platinum compounds as first-line chemotherapy for stage III/IV squamous non-small cell lung cancer.
Fang Y; Wang L; Xia GH; Shi MQ
Asian Pac J Cancer Prev; 2014; 15(17):7453-7. PubMed ID: 25227858
[TBL] [Abstract][Full Text] [Related]
38. Phase I study of Nedaplatin, a platinum based antineoplastic drug, combined with nab-paclitaxel in patients with advanced squamous non-small cell lung cancer.
Igawa S; Otani S; Nakahara Y; Ryuge S; Hiyoshi Y; Fukui T; Mitsufuji H; Kubota M; Katagiri M; Sato Y; Sasaki J; Masuda N
Invest New Drugs; 2018 Feb; 36(1):45-52. PubMed ID: 28466376
[TBL] [Abstract][Full Text] [Related]
39. Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy.
Weiss JM; Pennell N; Deal AM; Morgensztern D; Bradford DS; Crane J; West HJ; Lee C; Pecot C; Stevenson JP; Irvin W; Socinski M; Stinchcombe T; Villaruz LC; Muss HB
Cancer; 2020 Mar; 126(5):1060-1067. PubMed ID: 31943168
[TBL] [Abstract][Full Text] [Related]
40. Patient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin versus solvent-based paclitaxel plus carboplatin for advanced non-small-cell lung cancer.
Hirsh V; Okamoto I; Hon JK; Page RD; Orsini J; Sakai H; Zhang H; Renschler MF; Socinski MA
J Thorac Oncol; 2014 Jan; 9(1):83-90. PubMed ID: 24346096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
